Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Buy" by Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.67.

PSNL has been the topic of a number of analyst reports. Craig Hallum initiated coverage on Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price objective on the stock. HC Wainwright lifted their price target on shares of Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 target price on shares of Personalis in a research report on Thursday, April 10th. Finally, Guggenheim assumed coverage on shares of Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 target price for the company.

Institutional Investors Weigh In On Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in PSNL. Royal Bank of Canada increased its stake in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after acquiring an additional 2,395 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after acquiring an additional 2,724 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Personalis during the 4th quarter worth approximately $28,000. Stifel Financial Corp grew its stake in shares of Personalis by 25.0% during the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after purchasing an additional 5,654 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Price Performance

Shares of NASDAQ PSNL traded down $0.05 during trading on Monday, hitting $5.81. 844,453 shares of the company were exchanged, compared to its average volume of 1,037,657. Personalis has a 1 year low of $1.14 and a 1 year high of $7.20. The firm's fifty day moving average price is $4.27 and its 200 day moving average price is $4.52. The company has a market cap of $513.17 million, a price-to-earnings ratio of -3.46 and a beta of 1.86.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. The company had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. On average, research analysts forecast that Personalis will post -1.4 earnings per share for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.